BioDlink International Company Limited
HHKEX:18753.35
HKD
-0.15
(-4.43%)
ISIN
HK0000545266
Return %
Stock
S&P 500
1Y
71.54
14.20
3Y
85.83
81.12
5Y
-20.36
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Shan Fu
- Full Time Employees
- 613
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 120 Changyang Street Suzhou JS China 215024
- IPO Date
- Nov 8, 2019
- Website
- totbiopharm.com
- Similar Companies
- Business
- BioDlink International Company Limited operates as a clinical-stage biopharmaceutical company primarily engaged in the research, development, manufacture, and marketing of anti-tumor drugs and biologics. Its core products include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), fusion proteins, and other bioconjugates. The company offers end-to-end biologics development services including process development, analytical development, CMC support, and commercial-scale GMP production of biologic therapies. BioDlink’s manufacturing capabilities extend to antibody drug substance production, ADC drug substance manufacturing, drug product filling including freeze-drying, and therapeutic biological drug commercialization. It provides global quality management and regulatory support complying with FDA, EMA, and NMPA GMP standards. The company supports clients through a flexible CDMO partnering model and operates a large-scale commercial GMP production base in Suzhou Industrial Park, China, with over 20,000L total manufacturing capacity and global GMP certifications. Founded in 2009 and headquartered in Suzhou, Jiangsu Province, China, BioDlink has built a fully integrated platform spanning discovery, process development, preclinical and clinical development, manufacturing, and commercialization. Its technology platforms encompass therapeutic monoclonal antibodies and ADCs, genetic engineering-based therapies including anti-tumor immunotherapy and gene therapy, and innovative drug delivery platforms with advanced targeted liposome administration systems. The company serves clients across Asia, Europe, and the Americas, actively expanding its presence with registrations and GMP approvals in over 30 overseas countries including Indonesia, Egypt, and Colombia. Recent major developments include a strategic alliance ecosystem with partners such as GlycanLink and Kexing Biopharm to expand full-service capabilities and strengthen commercialization of antibody drugs and ADCs. BioDlink added 20 new CDMO projects in the first half of 2024, with 17 focused on ADCs, accumulating 115 projects and 8 pre-BLA stage ADC programs. It launched a joint ADC site-specific conjugation technology platform called GL-DisacLink® with GlycanLink to enhance its pipeline and technology leadership. The company achieved a 49% sales volume increase in H1 2024 compared to 2023 and initiated registration applications in 31 overseas markets, targeting a first overseas product approval in the second half of 2024. Additionally, BioDlink restructured its board and committees effective October 2025 to support its international growth strategy. BioDlink International is listed on the Hong Kong Stock Exchange under ticker 1875.HK and continues to focus on its biopharmaceutical CDMO segment and oncology drug commercialization, emphasizing innovation in antibody-based conjugated drugs and expanding its global footprint through partnerships, new technology platforms, and regulatory certifications. Its commercialized product portfolio includes bevacizumab biosimilar (Pusintin®), approved for multiple cancer indications and gaining international regulatory approvals such as Nigeria's NAFDAC in 2025. The company’s integrated business model and robust R&D and manufacturing infrastructure position it as a leading partner in the global biologics and anti-tumor drug markets.